Karin Fijnvandraat

Professor
Amsterdam UMC, University of Amsterdam, Emma Children’s Hospital, Pediatric Hematology Amsterdam, Netherlands
Amsterdam, Noord-Holland, Netherlands

Presentation(s):

• LB 01.1 - Efanesoctocog Alfa Prophylaxis for Previously Treated Patients <12 Years of Age With Severe Hemophilia A

  Sunday, June 25, 2023
  10:45 – 11:00 ET

• PB0152 - The spectrum of FVIII-specific antibodies in persons with hemophilia A: a cross-sectional nationwide population study

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• OC 44.3 - Exploring red blood cells as a novel tolerogenic approach for factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

  Monday, June 26, 2023
  15:15 – 15:30 ET

• PB0623 - An enriched population pharmacokinetic model for recombinant factor IX-Fc fusion including young children with haemophilia B

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0642 - Determinants of the bleeding phenotype in persons with non-severe hemophilia

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0671 - Poor correlation between biomarkers and MRI-detected joint damage in a cross-sectional study of persons with non-severe hemophilia A

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0698 - Determinants of desmopressin response in bleeding disorders: a systematic review and meta-analysis

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0824 - Prospective longitudinal evaluation shows increase of VWF and FVIII activity with age in patients with type 1 and 2 Von Willebrand disease

  Monday, June 26, 2023
  18:30 – 19:30 ET